Novo Nordisk A/S

Industry / private company


Location: Kopenhagen (Copenhagen), Denmark (DK) DK

ISNI: 0000000403912646

ROR: https://ror.org/0435rc536

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial (2023) McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JF, Marx N, Mulvagh SL, et al. Journal article Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2022) Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, Mann JF, et al. Journal article Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis (2021) Mann J, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, Vilsboll T, et al. Journal article Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) Persson F, Bain SC, Mosenzon O, Heerspink HJL, Mann J, Pratley R, Raz I, et al. Journal article Case study about the influence of temperature and humidity for dimensional measurements on polymer parts (2021) Carli L, Binder F, Gasparin S, Sørensen BH, Andreasen JL, Kallasse MH Conference contribution, Abstract of lecture Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) Buse JB, Bain SC, Mann J, Nauck MA, Nissen SE, Pocock S, Poulter NR, et al. Journal article Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease (2020) Mann J, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, von Scholten BJ, Mosenzon O Journal article Targeted pharmacological therapy restores β-cell function for diabetes remission (2020) Sachs S, Bastidas-Ponce A, Tritschler S, Bakhti M, Boettcher A, Sanchez-Garrido MA, Tarquis-Medina M, et al. Journal article Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials (2020) Mann J, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P, Seufert J, et al. Journal article Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) Verma S, Bain SC, Honoré JB, Mann J, A. Nauck M, E. Pratley R, Rasmussen S, et al. Journal article
1 2 3